CABALETTA BIO, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
CABALETTA BIO, INC. (CABA) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 65.64 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- CABALETTA BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 67.91M shares, a 382.76% increase year-over-year.
- CABALETTA BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 14.07M shares, a 43.07% increase year-over-year.
- CABALETTA BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 9.83M shares, a 23.64% increase year-over-year.
- CABALETTA BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 7.95M shares, a 30.65% increase year-over-year.
- CABALETTA BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 66.93M shares, a 495.89% increase from fiscal 2024.
- CABALETTA BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 11.23M shares, a 37.96% increase from fiscal 2023.
- CABALETTA BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 8.14M shares, a 35.38% increase from fiscal 2022.
- CABALETTA BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.01M shares, a 41.25% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 65.64M shares 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | 67.91M shares 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | 66.93M shares 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | 66.71M shares 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | 67.33M shares 10-Q · filed 2026-08-13 | ||||
| 2025-03-31 | 14.07M shares 10-Q · filed 2026-05-14 | ||||
| 2024-12-31 | 11.23M shares 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | 10.61M shares 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | 10.25M shares 10-Q · filed 2025-08-07 | ||||
| 2024-03-31 | 9.83M shares 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | 8.14M shares 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | 8.20M shares 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | 8.08M shares 10-Q · filed 2024-08-08 | ||||
| 2023-03-31 | 7.95M shares 10-Q · filed 2024-05-15 | ||||
| 2022-12-31 | 6.01M shares 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | 6.08M shares 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | 6.13M shares 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | 6.09M shares 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | 4.26M shares 10-K · filed 2023-03-16 | ||||
| 2021-09-30 | 4.04M shares 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | 3.95M shares 10-Q · filed 2022-08-11 | ||||
| 2021-03-31 | 4.24M shares 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | 3.37M shares 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | 3.59M shares 10-Q · filed 2020-11-10 | ||||
| 2020-06-30 | 3.75M shares 10-Q · filed 2021-08-05 | ||||
| 2020-03-31 | 3.59M shares 10-Q · filed 2021-11-01 | 3.82M shares 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | 3.52M shares 10-K · filed 2021-03-16 | ||||
| 2019-09-30 | 22.92M shares 10-Q · filed 2020-11-10 | ||||
| 2019-06-30 | 22.83M shares 10-Q · filed 2020-08-06 | ||||
| 2019-03-31 | 23.04M shares 10-Q · filed 2020-05-12 | ||||
| 2018-12-31 | 15.75M shares 10-K · filed 2020-03-30 | ||||
| 2018-09-30 | 2.39M shares 10-Q · filed 2019-12-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |